secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001641489-25-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025
--------------------------------------------------------------------------------

- Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.
- FY2024 net loss attributable to shareholders $18.5M ($3.20/share) vs $20.3M ($9.71/share) in FY2023.
- Cash $36.7M at Dec 31, 2024, up from $9.4M a year earlier, boosted by private placement and ATM offering.
- Appointed Martin Lafontaine as Chief Commercial Officer; he brings over 25 years of diabetes commercial experience.
- R&D expenses fell to $11.5M in FY2024 from $13.6M in FY2023, due to reduced cadisegliatin costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/0001641489-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/vtvt-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001641489-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer